Pharming (PHAR) Total Current Liabilities (2019 - 2026)

Pharming (PHAR) has 8 years of Total Current Liabilities data on file, last reported at $93.2 million in Q2 2026.

• Quarterly Total Current Liabilities rose 6.03% year-over-year to $93.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $93.2 million (up 6.03% YoY) and the FY2025 annual result came in at $115.8 million, up 56.89% from the prior year.
• Total Current Liabilities eased to $93.2 million in Q2 2026, from $112.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $207.3 million in Q1 2024 to a low of $46694.0 in Q3 2022.
• A 5-year average of $80.0 million and a median of $77.8 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 99.9% — and 2023, when it soared 145653.2%.
• Tracing PHAR's Total Current Liabilities over 5 years: stood at $59.7 million in 2022, then soared by 30.6% to $78.0 million in 2023, then retreated by 5.34% to $73.8 million in 2024, then soared by 56.89% to $115.8 million in 2025, then decreased by 19.47% to $93.2 million in 2026.
• The last three Total Current Liabilities figures came in at $93.2 million (Q2 2026), $112.3 million (Q1 2026), and $115.8 million (Q4 2025), per Business Quant data.